Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise.
These adverse events ( AEs ) can have serious impact, and form a significant barrier to therapy adherence. Surveillance of post-marketing AEs is of vital importance to understand real-world AEs and reporting differences between individual statin drugs.
We conducted a review of post-approval muscle and tendon AE reports in association with statin use, to assess differences within the drug class.